Testosterone has a significant and direct effect on the liver. The liver contains androgen receptors that respond to testosterone, and through these receptors, the hormone influences how your liver processes sugar, stores cholesterol, and breaks down fat. Whether that influence is helpful or harmful depends largely on your testosterone levels, how you’re getting testosterone into your body, and the dose.
How Testosterone Works Inside the Liver
Your liver cells have androgen receptors that bind to testosterone and trigger changes in gene activity. When testosterone activates these receptors, it increases the expression of insulin receptors on liver cells and promotes glycogen synthesis, which is your liver’s way of storing sugar for later use. Testosterone also regulates a key glucose transporter protein called GLUT2, which controls how sugar moves in and out of liver cells. In animal studies, removing testosterone (through castration) caused these glucose-handling systems to break down, and restoring testosterone brought them back to normal.
Testosterone also shapes how your liver handles cholesterol. It boosts the uptake of LDL cholesterol from the bloodstream into the liver while simultaneously reducing the liver’s ability to convert cholesterol into bile and remove it. The net result is that more cholesterol accumulates in the liver over time with chronic testosterone exposure. This is one reason clinicians monitor cholesterol levels in men on long-term testosterone therapy.
Low Testosterone and Fatty Liver Disease
Men with low testosterone face a meaningful risk of developing non-alcoholic fatty liver disease (NAFLD). The connection runs in both directions: low testosterone promotes fat accumulation in the liver, and liver disease itself can suppress testosterone production. The prevalence of fatty liver disease in men with clinically low testosterone is considerable, driven by overlapping mechanisms including increased fat storage, insulin resistance, and chronic low-grade inflammation.
In one long-term study following hypogonadal men over eight years, testosterone treatment did not worsen liver enzyme levels. Both AST and ALT, the standard markers of liver cell damage, stayed within normal ranges throughout the study period. In fact, prior research on 225 men with low testosterone found that AST and ALT levels declined over five years of treatment. The pattern at baseline in these men often resembled the biochemical signature of fatty liver, with ALT running higher than AST, suggesting that many already had some degree of liver fat before starting therapy.
Testosterone’s Effect on Cholesterol Processing
One of the most well-documented liver effects involves an enzyme called hepatic lipase, which breaks down fats in lipoproteins. Testosterone is a potent stimulator of this enzyme. In one study, testosterone administration increased hepatic lipase activity by more than 60% above baseline within just three weeks. That spike drove down HDL cholesterol (the protective kind) and shifted LDL particles toward a smaller, denser form that is more strongly associated with cardiovascular risk.
This is a real trade-off. Testosterone therapy can improve metabolic health in men who are genuinely deficient, but the cholesterol changes it triggers in the liver are unfavorable from a heart-health perspective. It’s one of the main reasons regular bloodwork matters during treatment.
Oral Steroids Carry the Highest Liver Risk
Not all forms of testosterone affect the liver equally, and this distinction is critical. Natural, unmodified testosterone can’t survive the digestive process, so it has to be delivered through injections, skin patches, or gels. These forms bypass the liver’s first-pass metabolism and have a relatively clean safety profile. Cholestasis, a condition where bile flow from the liver is blocked, has not been described in patients receiving unmodified testosterone by injection or patch.
The problems arise with oral steroids that have been chemically altered at a specific position on the molecule (called C-17 alpha alkylation) to resist breakdown in the liver. This modification is what makes oral anabolic steroids like methyltestosterone survivable through digestion, but it also forces the liver to process the drug directly and repeatedly. These oral compounds are responsible for the vast majority of serious liver injuries linked to androgens, including cholestasis, elevated liver enzymes, and more dangerous complications. The Endocrine Society specifically recommends against oral methyltestosterone for this reason.
Liver Tumors From Androgen Use
Long-term or high-dose androgen use can cause liver tumors. The most common type is hepatocellular adenoma, a benign growth that is typically solitary and produces no symptoms until it causes problems. These tumors were first recognized in patients taking androgens for blood disorders like Fanconi anemia, but they’ve also appeared in bodybuilders using anabolic steroids, transgender men on hormone therapy, and people with conditions that cause excess androgen production.
These adenomas are not harmless just because they’re non-cancerous. Up to 52% of hepatocellular adenomas develop hemorrhage or rupture, and the symptomatic bleeding rate is around 14%. In one reported case, a 24-year-old man who had used injectable testosterone undecanoate starting at age 17 developed multiple liver adenomas and eventually experienced a sudden rupture causing severe abdominal pain. It is also well documented that prolonged androgen overstimulation can progress beyond adenomas to hepatocellular carcinoma, actual liver cancer.
Testosterone Therapy in Men With Cirrhosis
For men who already have liver cirrhosis and low testosterone, replacement therapy appears to improve outcomes rather than worsen them. A large emulated clinical trial using a nationally representative cohort found that testosterone use in men with cirrhosis and hypogonadism was associated with 8% lower mortality. It also reduced the risk of new decompensation events, the dangerous complications of advanced liver disease. The benefits were especially clear for ascites requiring drainage (18% risk reduction) and variceal hemorrhage, a life-threatening type of internal bleeding (33% risk reduction).
Importantly, testosterone therapy in these patients did not increase the risk of liver cancer, with the hazard ratio remaining statistically indistinguishable from no effect. This suggests that physiologic testosterone replacement, meaning doses that restore normal levels rather than exceed them, does not accelerate cancer development in an already damaged liver.
What Gets Monitored During Therapy
If you’re on testosterone replacement, the standard monitoring schedule from the Endocrine Society includes bloodwork at 3 to 6 months after starting treatment, then at 12 months, and annually thereafter. The primary labs checked are testosterone levels and hematocrit (a measure of red blood cell concentration, since testosterone stimulates red blood cell production). If hematocrit rises above 54%, therapy is paused until levels come down.
Routine liver function testing isn’t explicitly mandated for men on injectable or transdermal testosterone, which reflects the low hepatotoxicity of these formulations. However, liver enzymes are commonly included in standard blood panels, and any unexplained elevations would prompt further investigation. For men using oral formulations or those with pre-existing liver conditions, closer liver monitoring is warranted.